Summertime...and OTCs make the livin' easier

Check out important updates from the FDA from over the past week.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The approval offers a first of its kind treatment option for patients living with nonerosive GERD.

The companies are marketing products that may violate Federal Trade Commission prohibition of “unfair and deceptive acts in the marketplace.”

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

The commercial product is expected to be available by the end of July.